Helsinn Group has agreed to partner with QED Therapeutics, an affiliate of BridgeBio Pharma, to develop and commercialise the latter’s fibroblast growth factor receptors 1-3 (FGFR1-3) inhibitor, infigratinib, in oncology and all other indications except for skeletal dysplasias. A regulatory filing was accepted by the US FDA in December 2020 for patients with previously treated advanced cholangiocarcinoma harbouring an FGFR2 gene fusion or rearrangement. The deal, which is worth up to US$2.45 B, comes just over three years after BridgeBio in-licensed infigratinib from Novartis for an undisclosed amount.